Integra Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>IL</div>
It appears Integra LifeSciences may not have a good chance to recover from the newest drop as its shares fell again. Integra LifeSciences's current daily volatility is 2.06 percent, with a beta of 0.23 and an alpha of -0.01 over DOW. As many baby boomers are still indifferent towards current volatility, Integra LifeSciences Holdings. What exactly are Integra LifeSciences shareholders getting in November?
Published over a month ago
View all stories for Integra LifeSciences | View All Stories
Is Integra LifeSciences (NASDAQ:IART) stock way too aggressive for baby boomers?
Integra LifeSciences Holdings currently holds roughly 360.98 M in cash with 207.36 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.28. Our trade recommendations tool can be used to complement Integra LifeSciences Holdings advice provided by experts. It analyzes the entity's potential to grow against your specific risk preferences and investment horizon.

How important is Integra LifeSciences's Liquidity

Integra LifeSciences financial leverage refers to using borrowed capital as a funding source to finance Integra LifeSciences Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Integra LifeSciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Integra LifeSciences's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Integra LifeSciences, but it might be worth checking our own buy vs. sell analysis

What is driving Integra LifeSciences Investor Appetite?

Integra LifeSciences holds Efficiency (Sharpe) Ratio of -0.0268, which attests that the entity had -0.0268% of return per unit of risk over the last month. Macroaxis standpoint towards determining the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Integra LifeSciences exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to check out Integra LifeSciences Risk Adjusted Performance of 0.0127, market risk adjusted performance of 0.0324, and Downside Deviation of 1.85 to validate the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will Integra LifeSciences continue to go mental?

Newest expected short fall is at -1.49. Integra LifeSciences Holdings has relatively low volatility with skewness of 0.42 and kurtosis of 1.18. However, we advise all investors to independently investigate Integra LifeSciences Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Conclusion on Integra LifeSciences

Whereas some companies in the medical devices industry are either recovering or due for a correction, Integra LifeSciences may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the newest economy, it is better to hold off any trading of Integra as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Integra LifeSciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Integra LifeSciences Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com